Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

被引:0
|
作者
T D Gould
J A Quiroz
J Singh
C A Zarate
H K Manji
机构
[1] Laboratory of Molecular Pathophysiology,
[2] National Institute of Mental Health,undefined
来源
Molecular Psychiatry | 2004年 / 9卷
关键词
depression; mania; pharmacology; manic-depressive illness; neurotrophic factors; valproic acid; PAP phosphatase; pramipexole; zinc;
D O I
暂无
中图分类号
学科分类号
摘要
Bipolar disorder afflicts approximately 1–3% of both men and women, and is coincident with major economic, societal, medical, and interpersonal consequences. Current mediations used for its treatment are associated with variable rates of efficacy and often intolerable side effects. While preclinical and clinical knowledge in the neurosciences has expanded at a tremendous rate, recent years have seen no major breakthroughs in the development of novel types of treatment for bipolar disorder. We review here approaches to develop novel treatments specifically for bipolar disorder. Deliberate (ie not by serendipity) treatments may come from one of two general mechanisms: (1) Understanding the mechanism of action of current medications and thereafter designing novel drugs that mimics these mechanism(s); (2) Basing medication development upon the hypothetical or proven underlying pathophysiology of bipolar disorder. In this review, we focus upon the first approach. Molecular and cellular targets of current mood stabilizers include lithium inhibitable enzymes where lithium competes for a magnesium binding site (inositol monophosphatase, inositol polyphosphate 1-phosphatase, glycogen synthase kinase-3 (GSK-3), fructose 1,6-bisphosphatase, bisphosphate nucleotidase, phosphoglucomutase), valproate inhibitable enzymes (succinate semialdehyde dehydrogenase, succinate semialdehyde reductase, histone deacetylase), targets of carbamazepine (sodium channels, adenosine receptors, adenylate cyclase), and signaling pathways regulated by multiple drugs of different classes (phosphoinositol/protein kinase C, cyclic AMP, arachidonic acid, neurotrophic pathways). While the task of developing novel medications for bipolar disorder is truly daunting, we are hopeful that understanding the mechanism of action of current mood stabilizers will ultimately lead clinical trials with more specific medications and thus better treatments those who suffer from this devastating illness.
引用
收藏
页码:734 / 755
页数:21
相关论文
共 41 条
  • [1] Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers
    Gould, TD
    Quiroz, JA
    Singh, J
    Zarate, CA
    Manji, HK
    MOLECULAR PSYCHIATRY, 2004, 9 (08) : 734 - 755
  • [2] Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology
    Quiroz, JA
    Singh, J
    Gould, TD
    Denicoff, KD
    Zarate, CD
    Manji, HK
    MOLECULAR PSYCHIATRY, 2004, 9 (08) : 756 - 776
  • [3] Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology
    J A Quiroz
    J Singh
    T D Gould
    K D Denicoff
    C A Zarate
    H K Manji
    Molecular Psychiatry, 2004, 9 : 756 - 776
  • [4] The molecular and cellular actions of mood-stabilizers
    Chen, G
    BEHAVIOURAL PHARMACOLOGY, 2003, 14 : S4 - S5
  • [5] Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of improved therapeutics
    Manji, HK
    Zarate, CA
    MOLECULAR PSYCHIATRY, 2002, 7 (Suppl 1) : S1 - S7
  • [6] Molecular and cellular mechanisms underlying mood stabilization in bipolar disorder: implications for the development of improved therapeutics
    H K Manji
    C A Zarate
    Molecular Psychiatry, 2002, 7 : S1 - S7
  • [7] Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers
    Gentile, Salvatore
    BIPOLAR DISORDERS, 2006, 8 (03) : 207 - 220
  • [8] Genetic Influences on Response to Mood Stabilizers in Bipolar Disorder Current Status of Knowledge
    Rybakowski, Janusz K.
    CNS DRUGS, 2013, 27 (03) : 165 - 173
  • [9] Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers
    Manji, HK
    Moore, GJ
    Chen, G
    BRITISH JOURNAL OF PSYCHIATRY, 2001, 178 : S107 - S119
  • [10] Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder
    Xie, XM
    Hagan, RM
    NEUROPSYCHOBIOLOGY, 1998, 38 (03) : 119 - 130